Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Declines By 44.0%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 4,200 shares, a decline of 44.0% from the April 30th total of 7,500 shares. Approximately 0.0% of the company's stock are short sold. Based on an average daily volume of 236,800 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, HC Wainwright upped their price target on shares of Armata Pharmaceuticals from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Monday, May 19th.

Armata Pharmaceuticals Trading Down 0.5%

Armata Pharmaceuticals stock traded down $0.01 during mid-day trading on Monday, reaching $1.94. The company had a trading volume of 15,746 shares, compared to its average volume of 69,262. Armata Pharmaceuticals has a 52 week low of $0.90 and a 52 week high of $3.42. The stock's 50 day simple moving average is $1.46. The stock has a market cap of $70.19 million, a price-to-earnings ratio of -1.18 and a beta of 0.87.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.